About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNANCT07456475

Metaverse Applications in Clinical Neurorehabiliation: Device Feasibility

The main objective of the TERSICORE project is the development of a new advanced set of exergames in the Metaverse that can be used in all clinical and home rehabilitation devices to improve the cogni...

Lead sponsor: Istituto per la Ricerca e l'Innovazione Biomedica•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Istituto per la Ricerca e l'Innovazione Biomedica

Collaborators

H.S.P.I. s.p.a.
Catholic University of the Sacred Heart
Fondazione Don Carlo Gnocchi Onlus

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Adult age: 18-85 years
•Education: at least 5 years
•Cognitive deficits at routine outpatient clinical neuropsychological assessment (at least one test with p.e. 0/1) in subjects with focal neurological insult - (post-Stroke, post-Cranial Trauma)
•neurodegenerative disorders - (Multiple Sclerosis, Parkinson's, Mild Cognitive Impairment, AD-like)

Exclusion Criteria

•Severe cognitive impairment MMSE \<22
•Presence of severe deficits in visual acuity, hearing perception, communication and severe dysmetria, such as to interfere with the administration of the activities proposed by TERSICORE

Related studies

Apathy in Parkinson Disease TMS Study

NCT06087926 · Parkinson Disease

Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury

NCT07663266 · Multiple Sclerosis, Spinal Cord Injury

RECRUITINGPhase 3

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

NCT07642908 · Parkinson Disease

RECRUITINGPhase 2

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830 · Parkinson Disease, Parkinson, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 6, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhaseNA

Enrollment25

Start dateJun 2025

Last updatedMar 6, 2026

Condition

Neurological Disorder Multiple Sclerosis Parkinson Disease Stroke Traumatic Brain Injury

Locations shown

Fondazione Don Gnocchi

Milan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions